FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2983004004> ?p ?o ?g. }

• W2983004004 endingPage "e219" @default.
• W2983004004 startingPage "e208" @default.
• W2983004004 abstract "Background Type I interferons are involved in systemic lupus erythematosus (SLE) pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1, suppressed interferon gene signatures and substantially reduced SLE disease activity. Here, we sought to confirm the efficacy of anifrolumab versus placebo in a phase 3 trial of adult patients with SLE and moderate-to-severe disease activity despite standard-of-care treatment. Methods TULIP-1 was a double-blind, randomised, controlled, phase 3 trial done at 123 sites in 18 countries. Included patients were aged 18–70 years, with moderate-to-severe SLE, and ongoing stable treatment with either prednisone or equivalent, an antimalarial, azathioprine, mizoribine, mycophenolate mofetil or mycophenolic acid, or methotrexate. Patients were randomly assigned (2:1:2) to receive placebo, anifrolumab 150 mg, or anifrolumab 300 mg intravenously every 4 weeks for 48 weeks. Stable standard-of-care treatment continued except for mandatory attempts at oral corticosteroid tapering for patients receiving prednisone or equivalent of 10 mg/day or more at baseline. The primary outcome was the difference between the proportion of patients who achieved an SLE responder index-4 (SRI-4) response at week 52 with anifrolumab 300 mg versus with placebo. Key secondary outcomes were the difference between the anifrolumab 300 mg group and the placebo group in: proportion of patients in the interferon gene signature test—high subgroup who achieved SRI-4 at week 52; proportion of patients on 10 mg/day or more corticosteroids at baseline who achieved a sustained dose reduction to 7·5 mg/day or less from week 40 to 52; proportion of patients with a cutaneous lupus erythematosus disease area and severity index (CLASI) activity score of 10 or higher at baseline who achieved a 50% or more reduction in CLASI score by week 12; proportion of patients who achieved SRI-4 at week 24; and annualised flare rate through week 52. Other measures of disease activity were also assessed at week 52, including the British Isles Lupus Assessment Group-based composite lupus assessment (BICLA). Safety was also assessed. Efficacy and safety analyses were done in the population of patients who received at least one dose of study drug. This trial was registered at ClinicalTrials.gov (NCT02446912). Findings Between June 9, 2015, and June 16, 2017, 457 patients were randomly assigned to the anifrolumab 300 mg group (n=180), the anifrolumab 150 mg group (n=93), or the placebo group (n=184). The proportion of patients at week 52 with an SRI-4 response was similar between anifrolumab 300 mg (65 [36%] of 180) and placebo (74 [40%] of 184; difference −4·2 [95% CI −14·2 to 5·8], p=0·41). Similarly, proportions of patients with an SRI-4 response at week 24, and at week 52 in patients in the interferon gene signature test—high subgroup, did not differ between the anifrolumab and placebo groups. In patients with baseline oral corticosteroids of at least 10 mg/day, sustained dose reduction to 7·5 mg/day or less was achieved by 42 (41%) of 103 patients in the anifrolumab 300 mg group and 33 (32%) of 102 patients in the placebo group (difference 8·9 [95% CI −4·1 to 21·9]). In patients with CLASI activity score of at least 10 at baseline, at least 50% reduction by week 12 was achieved by 24 (42%) of 58 patients in the anifrolumab 300 mg group and 14 (25%) of 54 in the placebo group (difference 17·0 [95% CI −0·3 to 34·3]). Annualised flare rates were 0·60 for anifrolumab and 0·72 for placebo (rate ratio 0·83 [95% CI 0·60 to 1·14]). BICLA response was achieved by 67 (37%) of 180 patients receiving anifrolumab 300 mg versus 49 (27%) of 184 receiving placebo (difference 10·1 [95% CI 0·6 to 19·7]). Anifrolumab's safety profile was similar to that observed in phase 2, with similar proportions of patients having a serious adverse event between groups (25 [14%] of 180 for anifrolumab 300 mg, ten [11%] of 93 for anifrolumab 150 mg, and 30 [16%] of 184 for placebo). Interpretation The primary endpoint was not reached. However, several secondary endpoints, including reduction in oral corticosteroid dose, CLASI responses, and BICLA responses, suggest clinical benefit of anifrolumab compared with placebo. Conclusive evidence for the efficacy of anifrolumab awaits further phase 3 trial data. Despite the inherent limitations of a 1-year phase 3 study, such as incomplete knowledge of applicability to the general population and scarce detection of rare safety signals, in addition to complications from prespecified restricted medication rules, our results suggest that anifrolumab might have the potential to provide a treatment option for patients who have active SLE while receiving standard therapy. Funding AstraZeneca. Type I interferons are involved in systemic lupus erythematosus (SLE) pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1, suppressed interferon gene signatures and substantially reduced SLE disease activity. Here, we sought to confirm the efficacy of anifrolumab versus placebo in a phase 3 trial of adult patients with SLE and moderate-to-severe disease activity despite standard-of-care treatment. TULIP-1 was a double-blind, randomised, controlled, phase 3 trial done at 123 sites in 18 countries. Included patients were aged 18–70 years, with moderate-to-severe SLE, and ongoing stable treatment with either prednisone or equivalent, an antimalarial, azathioprine, mizoribine, mycophenolate mofetil or mycophenolic acid, or methotrexate. Patients were randomly assigned (2:1:2) to receive placebo, anifrolumab 150 mg, or anifrolumab 300 mg intravenously every 4 weeks for 48 weeks. Stable standard-of-care treatment continued except for mandatory attempts at oral corticosteroid tapering for patients receiving prednisone or equivalent of 10 mg/day or more at baseline. The primary outcome was the difference between the proportion of patients who achieved an SLE responder index-4 (SRI-4) response at week 52 with anifrolumab 300 mg versus with placebo. Key secondary outcomes were the difference between the anifrolumab 300 mg group and the placebo group in: proportion of patients in the interferon gene signature test—high subgroup who achieved SRI-4 at week 52; proportion of patients on 10 mg/day or more corticosteroids at baseline who achieved a sustained dose reduction to 7·5 mg/day or less from week 40 to 52; proportion of patients with a cutaneous lupus erythematosus disease area and severity index (CLASI) activity score of 10 or higher at baseline who achieved a 50% or more reduction in CLASI score by week 12; proportion of patients who achieved SRI-4 at week 24; and annualised flare rate through week 52. Other measures of disease activity were also assessed at week 52, including the British Isles Lupus Assessment Group-based composite lupus assessment (BICLA). Safety was also assessed. Efficacy and safety analyses were done in the population of patients who received at least one dose of study drug. This trial was registered at ClinicalTrials.gov (NCT02446912). Between June 9, 2015, and June 16, 2017, 457 patients were randomly assigned to the anifrolumab 300 mg group (n=180), the anifrolumab 150 mg group (n=93), or the placebo group (n=184). The proportion of patients at week 52 with an SRI-4 response was similar between anifrolumab 300 mg (65 [36%] of 180) and placebo (74 [40%] of 184; difference −4·2 [95% CI −14·2 to 5·8], p=0·41). Similarly, proportions of patients with an SRI-4 response at week 24, and at week 52 in patients in the interferon gene signature test—high subgroup, did not differ between the anifrolumab and placebo groups. In patients with baseline oral corticosteroids of at least 10 mg/day, sustained dose reduction to 7·5 mg/day or less was achieved by 42 (41%) of 103 patients in the anifrolumab 300 mg group and 33 (32%) of 102 patients in the placebo group (difference 8·9 [95% CI −4·1 to 21·9]). In patients with CLASI activity score of at least 10 at baseline, at least 50% reduction by week 12 was achieved by 24 (42%) of 58 patients in the anifrolumab 300 mg group and 14 (25%) of 54 in the placebo group (difference 17·0 [95% CI −0·3 to 34·3]). Annualised flare rates were 0·60 for anifrolumab and 0·72 for placebo (rate ratio 0·83 [95% CI 0·60 to 1·14]). BICLA response was achieved by 67 (37%) of 180 patients receiving anifrolumab 300 mg versus 49 (27%) of 184 receiving placebo (difference 10·1 [95% CI 0·6 to 19·7]). Anifrolumab's safety profile was similar to that observed in phase 2, with similar proportions of patients having a serious adverse event between groups (25 [14%] of 180 for anifrolumab 300 mg, ten [11%] of 93 for anifrolumab 150 mg, and 30 [16%] of 184 for placebo). The primary endpoint was not reached. However, several secondary endpoints, including reduction in oral corticosteroid dose, CLASI responses, and BICLA responses, suggest clinical benefit of anifrolumab compared with placebo. Conclusive evidence for the efficacy of anifrolumab awaits further phase 3 trial data. Despite the inherent limitations of a 1-year phase 3 study, such as incomplete knowledge of applicability to the general population and scarce detection of rare safety signals, in addition to complications from prespecified restricted medication rules, our results suggest that anifrolumab might have the potential to provide a treatment option for patients who have active SLE while receiving standard therapy." @default.
• W2983004004 created "2019-11-22" @default.
• W2983004004 creator A5009908322 @default.
• W2983004004 creator A5013861508 @default.
• W2983004004 creator A5014912299 @default.
• W2983004004 creator A5022011236 @default.
• W2983004004 creator A5023290270 @default.
• W2983004004 creator A5027057428 @default.
• W2983004004 creator A5036616134 @default.
• W2983004004 creator A5039414460 @default.
• W2983004004 creator A5041299806 @default.
• W2983004004 creator A5047807604 @default.
• W2983004004 creator A5056194172 @default.
• W2983004004 creator A5068221099 @default.
• W2983004004 creator A5076651506 @default.
• W2983004004 date "2019-12-01" @default.
• W2983004004 modified "2023-10-09" @default.
• W2983004004 title "Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial" @default.
• W2983004004 cites W1796526928 @default.
• W2983004004 cites W1920228500 @default.
• W2983004004 cites W2011818634 @default.
• W2983004004 cites W2036095604 @default.
• W2983004004 cites W2047342378 @default.
• W2983004004 cites W2070527591 @default.
• W2983004004 cites W2091468965 @default.
• W2983004004 cites W2109507823 @default.
• W2983004004 cites W2111416025 @default.
• W2983004004 cites W2113844939 @default.
• W2983004004 cites W2117491442 @default.
• W2983004004 cites W2131457901 @default.
• W2983004004 cites W2135252441 @default.
• W2983004004 cites W2136149088 @default.
• W2983004004 cites W2139198208 @default.
• W2983004004 cites W2141455950 @default.
• W2983004004 cites W2144728634 @default.
• W2983004004 cites W2146203649 @default.
• W2983004004 cites W2161083732 @default.
• W2983004004 cites W2168146874 @default.
• W2983004004 cites W2206541367 @default.
• W2983004004 cites W2308059048 @default.
• W2983004004 cites W2514488813 @default.
• W2983004004 cites W2529156742 @default.
• W2983004004 cites W2556359407 @default.
• W2983004004 cites W2595973298 @default.
• W2983004004 cites W2765228582 @default.
• W2983004004 cites W2766830060 @default.
• W2983004004 cites W2767602096 @default.
• W2983004004 cites W2791265241 @default.
• W2983004004 cites W2791624485 @default.
• W2983004004 cites W2796401459 @default.
• W2983004004 cites W2807988321 @default.
• W2983004004 cites W2908226920 @default.
• W2983004004 cites W2909900992 @default.
• W2983004004 cites W2947593190 @default.
• W2983004004 doi "https://doi.org/10.1016/s2665-9913(19)30076-1" @default.
• W2983004004 hasPublicationYear "2019" @default.
• W2983004004 type Work @default.
• W2983004004 sameAs 2983004004 @default.
• W2983004004 citedByCount "215" @default.
• W2983004004 countsByYear W29830040042019 @default.
• W2983004004 countsByYear W29830040042020 @default.
• W2983004004 countsByYear W29830040042021 @default.
• W2983004004 countsByYear W29830040042022 @default.
• W2983004004 countsByYear W29830040042023 @default.
• W2983004004 crossrefType "journal-article" @default.
• W2983004004 hasAuthorship W2983004004A5009908322 @default.
• W2983004004 hasAuthorship W2983004004A5013861508 @default.
• W2983004004 hasAuthorship W2983004004A5014912299 @default.
• W2983004004 hasAuthorship W2983004004A5022011236 @default.
• W2983004004 hasAuthorship W2983004004A5023290270 @default.
• W2983004004 hasAuthorship W2983004004A5027057428 @default.
• W2983004004 hasAuthorship W2983004004A5036616134 @default.
• W2983004004 hasAuthorship W2983004004A5039414460 @default.
• W2983004004 hasAuthorship W2983004004A5041299806 @default.
• W2983004004 hasAuthorship W2983004004A5047807604 @default.
• W2983004004 hasAuthorship W2983004004A5056194172 @default.
• W2983004004 hasAuthorship W2983004004A5068221099 @default.
• W2983004004 hasAuthorship W2983004004A5076651506 @default.
• W2983004004 hasBestOaLocation W29830040042 @default.
• W2983004004 hasConcept C126322002 @default.
• W2983004004 hasConcept C159654299 @default.
• W2983004004 hasConcept C16005928 @default.
• W2983004004 hasConcept C203014093 @default.
• W2983004004 hasConcept C2775915377 @default.
• W2983004004 hasConcept C2776178377 @default.
• W2983004004 hasConcept C71924100 @default.
• W2983004004 hasConceptScore W2983004004C126322002 @default.
• W2983004004 hasConceptScore W2983004004C159654299 @default.
• W2983004004 hasConceptScore W2983004004C16005928 @default.
• W2983004004 hasConceptScore W2983004004C203014093 @default.
• W2983004004 hasConceptScore W2983004004C2775915377 @default.
• W2983004004 hasConceptScore W2983004004C2776178377 @default.
• W2983004004 hasConceptScore W2983004004C71924100 @default.
• W2983004004 hasIssue "4" @default.
• W2983004004 hasLocation W29830040041 @default.
• W2983004004 hasLocation W29830040042 @default.
• W2983004004 hasOpenAccess W2983004004 @default.
• W2983004004 hasPrimaryLocation W29830040041 @default.

• next